CA3015577A1 - Agents d'augmentation de la secretion de cytokines anti-inflammatoires - Google Patents

Agents d'augmentation de la secretion de cytokines anti-inflammatoires Download PDF

Info

Publication number
CA3015577A1
CA3015577A1 CA3015577A CA3015577A CA3015577A1 CA 3015577 A1 CA3015577 A1 CA 3015577A1 CA 3015577 A CA3015577 A CA 3015577A CA 3015577 A CA3015577 A CA 3015577A CA 3015577 A1 CA3015577 A1 CA 3015577A1
Authority
CA
Canada
Prior art keywords
disease
agonist
syndrome
autoimmune
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3015577A
Other languages
English (en)
Inventor
Luc St-Onge
Benoit Gauthier
Nadia COBOVUILLEUMIER
David Pozo Perez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Sevilla
Fundacion Publica Andaluza Progreso y Salud
Original Assignee
Universidad de Sevilla
Fundacion Publica Andaluza Progreso y Salud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de Sevilla, Fundacion Publica Andaluza Progreso y Salud filed Critical Universidad de Sevilla
Publication of CA3015577A1 publication Critical patent/CA3015577A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3015577A 2015-03-31 2016-03-31 Agents d'augmentation de la secretion de cytokines anti-inflammatoires Abandoned CA3015577A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15382160.8 2015-03-31
EP15382160 2015-03-31
PCT/EP2016/057137 WO2016156531A1 (fr) 2015-03-31 2016-03-31 Agents d'augmentation de la sécrétion de cytokines anti-inflammatoires

Publications (1)

Publication Number Publication Date
CA3015577A1 true CA3015577A1 (fr) 2016-10-06

Family

ID=52823578

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3015577A Abandoned CA3015577A1 (fr) 2015-03-31 2016-03-31 Agents d'augmentation de la secretion de cytokines anti-inflammatoires

Country Status (2)

Country Link
CA (1) CA3015577A1 (fr)
WO (1) WO2016156531A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115515580A (zh) * 2020-03-11 2022-12-23 俄亥俄州国家创新基金会 使用碳硼烷和碳硼烷类似物调节t细胞活化的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005082344A1 (fr) * 2004-02-24 2005-09-09 Smithkline Beecham Corporation Activateurs de lhr1 a titre de medicaments
WO2011144725A2 (fr) * 2010-05-20 2011-11-24 Fundación Pública Andaluza Progreso Y Salud Nouvelles méthodes de prévention ou de traitement du diabète

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115515580A (zh) * 2020-03-11 2022-12-23 俄亥俄州国家创新基金会 使用碳硼烷和碳硼烷类似物调节t细胞活化的方法

Also Published As

Publication number Publication date
WO2016156531A1 (fr) 2016-10-06

Similar Documents

Publication Publication Date Title
Ren et al. Melatonin signaling in T cells: Functions and applications
Liu et al. IL‐27 enhances the survival of tumor antigen‐specific CD8+ T cells and programs them into IL‐10‐producing, memory precursor‐like effector cells
Kaplan et al. The development and in vivo function of T helper 9 cells
Maywald et al. Zinc homeostasis and immunosenescence
Chiyo et al. Expression of IL‐27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals
Tasher et al. The genetic basis of severe combined immunodeficiency and its variants
US10821127B2 (en) Composition for inhibiting myeloid-derived suppressor cells comprising decitabine or its pharmaceutically acceptable salt as active ingredient
US9884098B2 (en) Multivalent breast cancer vaccine
ES2968038T3 (es) Agonista GLP-1R de acción prolongada como terapia de afecciones neurológicas y neurodegenerativas
ES2657675T3 (es) Terapia de enfermedad mediante el uso de una preparación farmacéutica tolerogénica
Tanaka et al. Oral ingestion of Lentinula edodes mycelia extract inhibits B16 melanoma growth via mitigation of regulatory T cell‐mediated immunosuppression
Kim et al. Delivery of IL-12p40 ameliorates DSS-induced colitis by suppressing IL-17A expression and inflammation in the intestinal mucosa
Marchi et al. Gene therapy with interleukin-10 receptor and interleukin-12 induces a protective interferon-γ-dependent response against B16F10-Nex2 melanoma
Lee et al. Bacillus‐derived poly‐γ‐glutamic acid attenuates allergic airway inflammation through a Toll‐like receptor‐4‐dependent pathway in a murine model of asthma
Hu et al. Characteristics of the interferon regulatory factor 5 (IRF5) and its expression in response to LCDV and poly I: C challenges in Japanese flounder, Paralichthys olivaceus
Wu et al. Matrine ameliorates spontaneously developed colitis in interleukin-10-deficient mice
Yang et al. Periplocoside A ameliorated type II collagen-induced arthritis in mice via regulation of the balance of Th17/Treg cells
TW202115102A (zh) 來自gpc3之胜肽、使用此胜肽之用於治療或預防癌症之醫藥組成物、免疫誘導劑、及抗原呈現細胞之製造方法
Perego et al. Guanabenz prevents d-galactosamine/lipopolysaccharide-induced liver damage and mortality
AU2014318889A1 (en) Dosage of a gluten peptide composition
Samarpita et al. Cyanidin restores Th17/Treg balance and inhibits T follicular helper cell differentiation via modulation of ROCK2 signaling in an experimental model of rheumatoid arthritis
CA3015577A1 (fr) Agents d'augmentation de la secretion de cytokines anti-inflammatoires
Chen et al. B lymphocyte stimulating factor of Trachinotus ovatus (TroBLyS) promotes antibacterial immune defense
Lee et al. Coenzyme Q10 exerts anti-inflammatory activity and induces Treg in graft versus host disease
US10030226B2 (en) Induced regulatory T cell and use thereof

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20200831